

# MODULE 4: PRESCRIPTION WRITING, REGULATION AND OTHER PROTOCOLS

# Indicators of best practice

- 1. Adequate discussion of dosing arrangements, clinical documentation and valid prescription provided to dosing point / pharmacy at commencement of and regularly during treatment
- 2. All prescriptions were valid / legal \*
- 3. All phone ordered or 'owing' prescriptions followed up with original prescription forwarded within 24 hours \*\*
- 4. All prescriptions sent directly to dosing point pharmacy
- 5. If prescribing depot buprenorphine, protocol followed for direct receipt of product (without patient handling)
- 6. Locum arrangements made and communicated to care team prior to taking leave
- 7. Where transfer of care is required, adequate communication, clinical handover and fulfilment of authority requirements occurred
- 8. Current NSW Health authority reflects current treatment
- Where takeaway doses authorised, prescription has clear instructions and guideline recommendations not exceeded \*\*\*
- \* in accordance with clause 80 of the Poisons and Therapeutic Goods Regulation
- \*\* in accordance with clause 81 of the Poisons and Therapeutic Goods Regulation
- \*\*\* variations must be clinically justified and documented in patient notes

# **Notes**

- Complete the self-audit for a random 10% sample (or at least 5 patients) being prescribed opioid agonist treatment.
- Use one audit form per patient record.
- Select the most appropriate options on the audit form based on what is **documented** in the patient records.
- Set targets to reach for each indicator (best practice is 100%)
- Calculate the results of the self-audit and develop an action plan to address identified gaps. Only one results sheet is required per self-audit cycle.
- Complete a follow up self-audit to measure the impacts of your action plan.

# Module 4: Prescription writing, regulation & other protocols

Methadone and buprenorphine are Schedule 8 (S8) drugs of addiction, and when prescribing such medicines, due care should be taken to ensure compliance with the Poisons and Therapeutic Goods legislation.

Patient initials:	Date of Birth:	_//		
Prescriber name:	Audit date: /	'/		
Auditor name/s:				
4.1 Prior to referri	ng the patient to a community pharmacy dosing site:			
	nt pharmacy was contacted to discuss dosing arrangements	Vaa	Na	NI/A
	mentation including patient ID was provided	Yes	No	N/A
·	tion was provided directly to the pharmacy (not given to the patient)	Yes	No	N/A
4.1.3 A Vallu prescrip	tion was provided directly to the pharmacy (not given to the patient)	Yes	No	N/A
4.2 All prescription	ns are written in accordance with clause 80 of the Poisons and Thera	apeutic Goods Reg	julation (	(PTGR) <sup>A</sup>
Yes N	lo			
<del>-</del>	of issue; name and address of the patient; name, strength and quantity (ex directions; maximum number of times the drug may be supplied on the pre		rds and fi	gures) of
-	e ordered or 'owing' prescriptions followed up by forwarding the original with clause 81 of the PTGR?	inal prescription w	vithin 24	hours,
Yes N	lo N/A			
4.4 All prescription	ns are forwarded directly to the dosing point/pharmacy and not giver	n to the patient		
Yes N	lo			
-	depot buprenorphine, a protocol is followed to ensure the product is lying pharmacy or from the wholesaler / distributor	received at the pra	actice dii	ectly
Yes N	lo N/A			
4.6 Prior to taking	leave, locum arrangements were made and:			
4.6.1 A handover wa	s performed and scripts were checked to be up to date	Yes	No	N/A
4.6.2 Communicated	to the care team (including dosing point / pharmacy)	Yes	No	N/A
4.6.3 PRU was notifi	ed in writing	Yes	No	N/A
	of locum arrangements	Yes	No	N/A
		163	140	19/7

### 4.7 If the patient has been transferred into your care or out of your care, there is documentation of

4.7.1 Clinical handover and communication with other prescriber	Yes	No	N/A
4.7.2 Regulatory requirements and mandatory notifications met in a timely way (including notification of transfer of doing site, exit forms if applicable)	Yes	No	N/A
4.7.3 Documentation of handover	Yes	No	N/A

# 4.8 Does the current NSW Health Authority in the patient records reflect the current treatment being provided?

Yes, the authority matches the treatment

No, the current authority does not match the treatment

There is no documented authority

### 4.9 If unsupervised ('take away') doses were prescribed:

4.9.1 Directions are clearly included on the prescription	Yes	No	N/A
4.9.2 Where guideline recommendations are exceeded, there is documentation of clinical justification in patient notes	Yes	No	N/A

Results table (use this template to record results following data collection)							
Indicator	Meets the indicator if	Y/N Pt 1	Y/N Pt 2	Y/N Pt 3	Y/N Pt 4	Y/N Pt 5	Total Y (%)
<ol> <li>Adequate discussion of dosing arrangements, clinical documentation and valid prescription provided to dosing point / pharmacy at commencement of treatment</li> </ol>	Q4.1 all are 'Yes' or 'N/A'						
2. All prescriptions were valid / legal	Q4.2 is 'Yes'						
All phone ordered or 'owing' prescriptions followed up with original prescription mailed within 24 hours	Q4.3 is 'Yes' or 'N/A'						
All prescriptions sent directly to dosing point pharmacy	Q4.4 is 'Yes'						
<ol><li>If prescribing depot buprenorphine, protocol followed for direct receipt of product (without patient handling)</li></ol>	Q4.5 is 'Yes' or 'N/A'						
6. Locum arrangements made and communicated to care team prior to taking leave	Q4.6 all are 'Yes' or 'N/A'						
7. Where transfer of care is required, adequate communication, clinical handover and fulfilment of authority requirements occurred	Q4.7 all are 'Yes' or 'N/A'						
Current NSW Health authority reflects current treatment	Q4.8 is 'Yes'						
Where takeaway doses authorised, prescription     has clear instructions and guideline     recommendations not exceeded	Q4.9 are all 'Yes' or 'N/A'						

Action plan (use this template to plan actions to address gaps and record dates of completion)					
Indicators where less than target 100% achieved	Planned actions to address gap	Date actions completed			

**Re-audit:** Following action plan completion, conduct another self-audit, eg after 3 months and compare the results.